Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FWY003 in geographic atrophy secondary to age-related macular degeneration
2025-523704-77-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in age-related macular degeneration (AMD) comparing FWY003 dose-ranging arm with Placebo arm (2 arms). Planned start May 2026; status: authorised.
02
Drugs
FWY003
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2025-523704-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523704-77-00.